ProVise Management Group’s AbbVie ABBV Stock Holding History

ProVise Management Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.34M	Sell	10,747 -142	-1%	-$31.5K	0.17%	97
2025 Q4	$2.49M	Buy	10,889 +503	+5%	+$115K	0.18%	97
2025 Q3	$2.4M	Buy	10,386 +50	+0.5%	+$10.2K	0.18%	98
2025 Q2	$1.92M	Sell	10,336 -251	-2%	-$46.6K	0.15%	103
2025 Q1	$2.22M	Sell	10,587 -1,786	-14%	-$347K	0.19%	98
2024 Q4	$2.2M	Sell	12,373 -3,985	-24%	-$733K	0.19%	99
2024 Q3	$3.23M	Sell	16,358 -658	-4%	-$123K	0.26%	94
2024 Q2	$2.92M	Sell	17,016 -404	-2%	-$66.9K	0.25%	96
2024 Q1	$3.17M	Sell	17,420 -2,149	-11%	-$370K	0.27%	92
2023 Q4	$3.03M	Sell	19,569 -59	-0.3%	-$8.6K	0.26%	100
2023 Q3	$2.93M	Sell	19,628 -1,672	-8%	-$245K	0.27%	98
2023 Q2	$2.87M	Sell	21,300 -48	-0.2%	-$7.04K	0.26%	95
2023 Q1	$3.4M	Sell	21,348 -3,562	-14%	-$545K	0.33%	82
2022 Q4	$4.03M	Sell	24,910 -2,389	-9%	-$366K	0.41%	70
2022 Q3	$3.66M	Sell	27,299 -395	-1%	-$56.7K	0.41%	72
2022 Q2	$4.24M	Sell	27,694 -4,137	-13%	-$632K	0.45%	69
2022 Q1	$5.16M	Sell	31,831 -29,742	-48%	-$4.32M	0.49%	54
2021 Q4	$8.34M	Sell	61,573 -2,583	-4%	-$305K	0.76%	36
2021 Q3	$6.92M	Sell	64,156 -10,508	-14%	-$1.2M	0.68%	41
2021 Q2	$8.41M	Sell	74,664 -2,299	-3%	-$259K	0.86%	26
2021 Q1	$8.33M	Buy	76,963 +61	+0.1%	+$6.53K	0.9%	22
2020 Q4	$8.24M	Sell	76,902 -246	-0.3%	-$23.6K	0.95%	24
2020 Q3	$6.76M	Buy	77,148 +1,592	+2%	+$150K	0.9%	29
2020 Q2	$7.42M	Buy	75,556 +19,968	+36%	+$1.76M	1.06%	20
2020 Q1	$4.24M	Buy	55,588 +32,660	+142%	+$2.78M	0.71%	41
2019 Q4	$2.03M	Sell	22,928 -40	-0.2%	-$3.32K	0.25%	108
2019 Q3	$1.74M	Buy	22,968 +5,537	+32%	+$380K	0.23%	117
2019 Q2	$1.27M	Sell	17,431 -95	-0.5%	-$7.47K	0.17%	131
2019 Q1	$1.41M	Hold	17,526	–	–	0.2%	123
2018 Q4	$1.62M	Sell	17,526 -100	-0.6%	-$8.79K	0.26%	102
2018 Q3	$1.67M	Buy	17,626 +340	+2%	+$32.2K	0.22%	120
2018 Q2	$8.54K	Sell	17,286 -3,077	-15%	-$301K	0.64%	48
2018 Q1	$1.93M	Sell	20,363 -20,368	-50%	-$2.24M	0.28%	99
2017 Q4	$3.94M	Sell	40,731 -3,081	-7%	-$290K	0.57%	55
2017 Q3	$3.89M	Sell	43,812 -2,315	-5%	-$176K	0.56%	51
2017 Q2	$3.34M	Buy	46,127 +16,712	+57%	+$1.12M	0.51%	59
2017 Q1	$1.92M	Buy	29,415 +4,125	+16%	+$259K	0.31%	95
2016 Q4	$1.58M	Sell	25,290 -600	-2%	-$36.6K	0.27%	107
2016 Q3	$1.63M	Buy	25,890 +2,750	+12%	+$178K	0.28%	102
2016 Q2	$1.43M	Sell	23,140 -9,021	-28%	-$550K	0.26%	107
2016 Q1	$1.84M	Buy	32,161 +2	+0%	+$111	0.38%	81
2015 Q4	$1.91M	Buy	32,159 +294	+0.9%	+$16.9K	0.4%	77
2015 Q3	$1.73M	Buy	31,865 +1,150	+4%	+$74.9K	0.4%	82
2015 Q2	$2.06M	Buy	30,715 +521	+2%	+$34K	0.44%	72
2015 Q1	$1.77M	Buy	30,194 +1,935	+7%	+$117K	0.37%	80
2014 Q4	$1.85M	Sell	28,259 -431	-2%	-$27.2K	0.4%	76
2014 Q3	$1.66M	Sell	28,690 -1,438	-5%	-$79.8K	0.36%	87
2014 Q2	$1.7M	Sell	30,128 -200	-0.7%	-$10.5K	0.37%	84
2014 Q1	$1.56M	Buy	30,328 +490	+2%	+$24.8K	0.38%	77
2013 Q4	$1.58M	Hold	29,838	–	–	0.41%	76
2013 Q3	$1.33M	Buy	29,838 +2,610	+10%	+$116K	0.38%	75
2013 Q2	$1.13M	Buy	+27,228	New	+$1.19M	0.33%	84

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ProVise Management Group's ABBV Position: Q1 2026 in Review

ProVise Management Group reduced its AbbVie (ABBV) stake by 1.3% in Q1 2026, selling an estimated $31.5K and leaving 10,747 shares worth $2.34M. The position accounts for 0.17% of the portfolio, ranked #97.

ProVise Management Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.41M in Q2 2021. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

ProVise Management Group held 10,747 shares of AbbVie worth $2.34M as of Q1 2026.
ProVise Management Group sold 142 AbbVie shares in Q1 2026, an estimated $31.5K.
AbbVie made up 0.17% of ProVise Management Group's portfolio in Q1 2026, its #97 holding.
ProVise Management Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
ProVise Management Group's AbbVie position peaked at $8.41M in Q2 2021.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on ProVise Management Group's 13F filing for Q1 2026, filed 7 May 2026.